Across outcomes, agent-level estimates for tirzepatide compared with placebo were predominantly low to very low certainty, driven by indirect-only evidence and imprecision
studied IC/BPS patients with Hunner lesions and abnormal bladder biopsy results (including histopathologic findings of inflammatory infiltrates, granulation tissue, overexpression of mast cells, and/or intrafascicular fibrotic changes), also called ESSIC type 3C disease ( Box 35.2 ), and compared them to IC/BPS patients with normal cystoscopy and biopsy results
Its not due to the drug
dual GLP-1/GIP RA often categorized with GLP-1 meds), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), exenatide (Bydureon, Byetta), and others like lixisenatide (Adlyxin) and oral semaglutide formulations
Wellness & Energy Stack Daily Wellness & Active Lifestyle Bundle
So we don't know it's purity, contaminants, things like that